Results of clinical and economic analysis of pharmacotherapy of patients epilepts
Abstract
Epilepsy is one of the most common serious diseases of the central nervous system in the world. The effective system of pharmaceutical care for epileptic patients requires the involvement of appreciable budgetary financial resources. In order to determine the actual state of pharmaceutical care to the population, clinical and economic studies are used, the results of which allow to optimize the cost of pharmacotherapy and ensure the implementation of the constitutional rights of Ukrainian citizens to available medical and pharmaceutical care.
The aim of the study was to conduct a clinical and economic analysis of pharmacotherapy of epilepsy.
The object of the study was the data of 118 medical records of patients diagnosed with epilepsy, who were treating at specialized healthcare facilities. Evaluation of the degree of pharmacotherapy rationality in epileptic patients was taken using frequency, VEN, ABC analysis.
The results of the investigation of patients’ medical records showed that 87 trade names of medications (76 international non-proprietary names of medications) were prescribed for epileptic patients. The total number of prescriptions is 918. The average number of prescriptions per patient is 7, which indicates polypragmasy. It was found that the leader in the number of appointments were carbamazepine – 11.11% of the total number of prescriptions and valproic acid – 3.49%. It is proved that in the structure of prescriptions for epileptic patients the part of medication with index V was 7.89%, which indicates a low degree of prescriptions compliance with healthcare standards. According to the results of the integrated ABC and VEN analysis, it was proved that among the groups A/V, A/E, A/N, the group A/V has the largest amount of expenditures – 36.38% of total cost. In general, group N accounts for 41.97% of total costs, which may indicate the irrational use of drugs in the provision of pharmaceutical care to epileptic patients.
The results of clinical and economic analysis of medical records of epileptic patients allowed to identify features in the organization of pharmaceutical care, as well as to substantiate the main directions of improving pharmacotherapy of epileptic patients with limited budget funding for healthcare.
References
World Health Organization. Sixty-eighth world health assembly. Resolutions and decisions annexes. Geneva. 2015. – URL: https://apps.who.int/gb/ebwha/pdf_files/WHA68-REC1/A68_R1_REC1-en.pdf
WHO Еpilepsy. 2019. – URL: https://www.who.int/ru/news-room/fact-sheets/detail/epilepsy
WHO Еpilepsy. 2019. A public health imperative. – URL: http://www.who.int/mental_health/neurology/epilepsy/report_2019/en_171.pdf
Volkova A. V., Korzh Yu. V., Oleinikova N. V. ta in. Doslidzhennia pokaznykiv zakhvoriuvanosti naselennia na epilepsiiu v Ukraini na derzhavnomu ta rehionalnomu rivniakh // Sotsialna farmatsiia v okhoroni zdorovia. – 2019. – T. 5, № 4. – S. 14–22. https://doi.org/10.24959/sphhcj.19.173
Zakhvoriuvanist ta poshyrenist rozladiv psykhiky ta povedinky. Derzhavnyi zaklad «Tsentr medychnoi statystyky MOZ Ukrainy» [Elektronnyi resurs]. – Rezhym dostupu: http://medstat. gov.ua/ukr/statdan.html
Faught E., Li X., Choi J. et al. Real-world analysis of hospitalizations in patients with epilepsy and treated with perampanel // Epilepsia Open. – 2021. – V. 6, N 4. – P. 645–652. https://doi.org/10.1002/epi4.125157
Mehta D., Davis M., Epstein A. J. et al. Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs // Clinicoecon. Outcomes. Res. – 2021. – V. 13. – P. 251–261. https://doi.org/10.2147/CEOR.S3030798
Kotvitska A. A., Prokopenko O. S. Kliniko-ekonomichne obgruntuvannia suchasnykh napriamkiv udoskonalennia farmatsevtychnoi dopomohy khvorym na khvorobu Parkinsona. – Kharkiv: NfaU, 2020. – 30 s.
Nemchenko A. S., Nazarkina V. N., Kurylenko Y. The study of the state of pharmaceutical provision for patients with cardiovascular diseases using ABC-and VEN-analyses // Visnyk farmatsii. – 2018. – № 3 (95). – S. 44–48. https://doi.org/10.24959/nphj.18.2218
Iakovlieva L. V., Bahlai T. O. Kliniko-ekonomichnyi analiz farmakoterapii khvorykh z toksychnymy urazhenniamy pechinky v ZOZ m. Kharkova // Ukr. biofarmats. zhurn. – 2020. – N 2 (63). – S. 36–43. https://doi.org/10.24959/ubphj.20.266
Matushchak M. R. et al. Rezultaty analizu likarskykh pryznachen ta struktury spozhyvannia preparativ khvorymy na limfohranulematoz v Ukraini // Sotsialna farmatsiia v okhoroni zdorovia. – 2021. – Т. 7, № 1. – S. 24–35. https://doi.org/10.24959/sphhcj.21.213
MOZ Ukrainy. Nakaz № 276 vid 17. 04. 2014 r. «Unifikovanyi klinichnyi protokol pervynnoi, ekstrenoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy epilepsii u doroslykh». – URL: http://mtd.dec.gov.ua/images/dodatki/2014_276_Epilepsii/2014_276_YKPMD_epi-lepsiya_dorosli.pdf
KMU. Postanova vid 23. 12. 2021 r. № 1431. «Pro vnesennia zmin do Natsionalnoho pereliku osnovnykh likarskykh zasobiv». – URL: https://zakon.rada.gov.ua/laws/show/1081-2017-%D0%BF#n8
MOZ Ukrainy. Nakaz vid 06. 05. 2020 r. № 1075 «Pro zatverdzhennia dvanadtsiatoho vypusku Derzhavnoho formuliara likarskykh zasobiv ta zabezpechennia yoho dostupnosti». – URL: https://moz.gov.ua/article/ministry-mandates/nakaz-moz-ukraini-vid-06052020--1075-pro-zatverdzhennja-dvanadcjatogo-vipusku-derzhavnogo-formuljara-likarskih-zasobiv-ta-zabezpechennja-jogo-dostupnosti
Fediak I. O., Kupnovytska I. H., Hrynyk N. R. Kliniko-ekonomichna otsinka farmakoterapii khvorykh na tuberkuloz u viddilenniakh intensyvnoi terapii protytuberkuloznykh dyspanseriv // Sotsialna farmatsiia v okhoroni zdorovia. – 2018. – T. 4, № 2. – S. 19–28. https://doi.org/10.24959/sphhcj.18.114
Nemchenko A. S., Balynska M. V. Rezultaty kliniko-ekonomichnoho analizu spozhyvannia likarskykh preparativ khvorymy dytiachoho viku na virusnu diareiu // Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii. – 2016. – № 3. – S. 60–67.
Perucca E. The pharmacological treatment of epilepsy: recent advances and future perspectives // Acta Epileptologica. – 2021. – N 3. https://doi.org/10.1186/s42494-021-00055-z
Tharavichitkun J., Yadee T., Angkaow P., Suansanae T. Evaluating Therapeutic Equivalence of Generic and Original Levetiracetam in Patients with Epilepsy: A Retrospective Study // Neurol. Int. – 2022. – V. 14, N 1. – P. 271–283. https://doi.org/10.3390/neurolint14010022
This work is licensed under a Creative Commons Attribution 4.0 International License.